[Peptide imaging: the somatostatine model]

Riferimento: 
Recenti Prog Med. 2012 Nov;103(11):404-9.
Autori: 
Prisco MR, Vaccaro A, Gatta G.
Fonte: 
Recenti Prog Med. 2012 Nov;103(11):404-9.
Anno: 
2012
Azione: 
L'approccio principale è stato l'uso di 111In Octreotide come imaging funzionale per individuare i tumori neuroendocrini (NET).
Target: 
111In Octreotide/tumori neuroendocrimi.

ABSTRACT
Radiolabeled cell-surface peptide receptor-binding molecules are emerging as an important class of radiopharmaceuticals. Main approach has been the use of 111In Octreotide as functional imaging to find NETs. In some tumor types, it is considered the diagnostic gold standard. This article focuses on the current status of peptide-receptor scintigraphy in different tumors, in other oncologic and non oncologic applications and on future developments in these fields.